La anemia hemolítica autoinmune (AHAI) es una alteración hematológica autoinmune producida por la síntesis de autoanticuerpos contra los antígenos propios. Estas representam as formas mais comuns de anemia hemolítica hereditária. .. quanto ao seu potencial carcinogênico67 em relação à população pediátrica. Recibido para publicación: Aceptado para publicación: Introducción. La anemia hemolítica microangiopática se describió por prime-.
|Published (Last):||9 March 2010|
|PDF File Size:||12.45 Mb|
|ePub File Size:||1.98 Mb|
|Price:||Free* [*Free Regsitration Required]|
Si continua navegando, consideramos que acepta su uso. The genomics of new drugs in sickle cell disease. High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin.
Pulmonary hypertension in sickle cell disease: Hepatic dysfunction in sickle cell disease: Overt and incomplete silent cerebral infarction pediatrla sickle cell anemia: Care of patients with haemoglobin abnormalities: Neuroimaging Clin N Am. The Impact Factor measures the average number of citations received in a particular year by papers published in the journal during the two receding years.
Corticoids represent the standard frontline therapeutic option for warm autoantibodies haemolytic anaemia.
You can change the settings or obtain more information by clicking here. Transient Donath-Lansteiner Haemolytic anaemia. J Womens Health Larchmt. Sildenafil therapy in patients with sickle cell disease and pulmonary hypertension.
The genetics of blood disorders: hereditary hemoglobinopathies
Fathallah H, Atweh GF. The role of hydroxyurea in the management of sickle cell disease. Expert Rev Mol Med. Acute myocardial infarction in sickle cell disease: Distinct HLA hemolitia by stroke subtype in children with sickle cell anemia. Kuypers FA, de Jong K. Identification of differentially expressed genes induced by hydroxyurea in reticulocytes from sickle cell anaemia patients.
Previous article Next article. The treatment of these autoimmune haemolytic anaemias with rituximab requires authorisation by the Spanish Ministry of Health for compassionate use. Clinically, it is characterized by microangiopathic hemolyticanemia, thrombocytopenia, neurologic abnormalities,fever and renal dysfunction. N Engl J Med. Biol Blood Marrow Transplant.
You can change the settings or obtain more information by clicking here. Parosysmal cold hemoglobinuria of nonsyphilitic etiology in two children.
The genetics of blood disorders: Estudio retrospectivo de 22 episodios consecutivos en 16 pacientes. Successful treatment of hemopitica thrombotic thrombocytopenic purpura with plasmapheresis and vincristine. Services on Demand Journal. Eur J Pediatr,pp.
DESTACAN LA UTILIDAD DEL RITUXIMAB PARA TRATAR LA ANEMIA HEMOLITICA AUTOIMMUNE
The anti-CD20 monoclonal antibody rituximab has gained widespread acceptance in the management of haematologic disorders with autoantibodies production. Laboratorydata typically reveal hemolytic anemia, with schistocyteson the peripheral smear, diminished serum haptoglobin,and thrombocytopenia. Lancet,pp. Adhesion molecules and hydroxyurea in the pathophysiology of sickle cell disease.
There was a problem providing the content you requested
J Pediatr,pp. Johnson C, Telen MJ. Normality has been maintained for36 and 24 months respectively, and the children have presentedno clinico-biological alterations.
Effect of cytokines and chemokines on sickle neutrophil adhesion to fibronectin. Risk factors for conjunctival and retinal vessel alterations in sickle cell disease.
Modification of globin gene expression by RNA targeting strategies.
Subscribe to our Newsletter. Correction of sickle cell disease by homologous recombination in embryonic stem cells. Evolution was favorable in both patients. Genetic dissection and prognostic modeling of overt stroke in sickle cell anemia. Am Psdiatria Trop Med Hyg. Microangiopathic hemolytic anemia and thrombocytopenia. Pediatira del alumnado con diabetes tipo 1 en Material and methods We present the clinical cases of two children, aged 4 and7 respectively, with TTP, but with different evolution andtreatment.
Clinical, genetic, and therapeutic insights into systemic mast cell disease. Claster S, Vichinsky EP.
Reversal of heart failure in thalassemia major by combined chelation therapy: